世卫组织建议使用GLP-1药物治疗成人肥胖症,敦促全球在专利到期时普及。 WHO recommends GLP-1 drugs for adult obesity, urging global access amid patent expirations.

世界卫生组织建议将Ozempic和Wegovy等GLP-1类药物作为成人肥胖症的长期治疗方法,这标志着与以前只注重改变生活方式的指南相比发生了重大转变。 The World Health Organization has recommended GLP-1 drugs like Ozempic and Wegovy as long-term treatments for adult obesity, marking a major shift from previous guidance that focused only on lifestyle changes. 新准则于2025年12月1日在日本医学协会发表,将肥胖列为慢性疾病,并强调将药物与饮食和锻炼结合起来。 The new guidelines, published in JAMA on December 1, 2025, classify obesity as a chronic disease and emphasize combining medication with diet and exercise. 虽然这些药品在减重和减少相关健康风险方面显示出成效,但世卫组织警告目前能够获得这些药品的不到10%的人,尤其是在中低收入国家。 While these drugs show effectiveness in weight loss and reducing related health risks, the WHO warns fewer than 10% of those who could benefit currently have access, especially in low- and middle-income countries. 本组织敦促制药公司采用分级定价、自愿许可和技术分享办法,以扩大供应,特别是在主要专利于2026年到期时。 The organization urges pharmaceutical companies to adopt tiered pricing, voluntary licensing, and technology sharing to expand availability, particularly as key patents expire in 2026.